John D. Ayers

Dr. John D. Ayers

Hematology | Oncology
4405 Weaver Pkwy, 
Waterman, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
31 Years of Experience
4405 Weaver Pkwy, 
Waterman, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Ayers is a Hematologist and an Oncologist in Waterman, Illinois. Dr. Ayers has been practicing medicine for over 31 years and is rated as an Experienced provider by MediFind in the treatment of Hemochromatosis. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Myelodysplastic Syndrome (MDS).

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Illinois At Chicago College Of Medicine, 1995.0
Residency
Boston University Medical Center
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine - Hematology (Certified)
Hospital Affiliations
Northwestern Medicine Delnor Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

4405 Weaver Pkwy, Waterman, IL 60555

Additional Areas of Focus

Dr. Ayers has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Melanoma
Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Device, Other
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Other, Procedure
Study Phase: Phase 2
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Enrollment Status: Completed
Publish Date: June 27, 2018
View 9 Less Clinical Trials
Similar Doctors
Advanced in Hemochromatosis
Dr. Leela Bhupalam
Hematology Oncology | Hematology | Oncology
Advanced in Hemochromatosis
Dr. Leela Bhupalam
Hematology Oncology | Hematology | Oncology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (18.0 miles away)
708-216-8372
Languages Spoken:
English, Hindi, Kannada
See accepted insurances
Accepting New Patients

Leela Bhupalam is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Bhupalam is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Angiosarcoma, and Bone Marrow Aspiration. Dr. Bhupalam is currently accepting new patients.

Advanced in Hemochromatosis
Dr. Victor R. Gordeuk
Hematology Oncology | Hematology | Oncology
Advanced in Hemochromatosis
Dr. Victor R. Gordeuk
Hematology Oncology | Hematology | Oncology
820 S Wood St, Sickle Cell Ctr. Suite 172, Clinical Sciences Building, 
Chicago, IL 
 (26.4 miles away)
312-996-5680
Languages Spoken:
English
See accepted insurances

Victor Gordeuk is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Gordeuk is rated as an Elite provider by MediFind in the treatment of Hemochromatosis. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant.

Advanced in Hemochromatosis
Dr. Arshad I. Husain
Oncology | Hematology | Hematology Oncology
Advanced in Hemochromatosis
Dr. Arshad I. Husain
Oncology | Hematology | Hematology Oncology

Franciscan Physician Network

1205 S Main St, Suite 101, 
Crown Point, IN 
 (51.4 miles away)
219-662-0077
Languages Spoken:
English, Hindi, Marathi, Urdu
See accepted insurances
Accepting New Patients

Arshad Husain is an Oncologist and a Hematologist in Crown Point, Indiana. Dr. Husain is rated as an Advanced provider by MediFind in the treatment of Hemochromatosis. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Anemia, Breast Cancer in Men, and Advanced Bronchoscopy. Dr. Husain is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ayers's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile